PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $55,911 | -31.7% | 3,352 | +13.1% | 0.00% | -25.0% |
Q2 2023 | $81,838 | +41.2% | 2,963 | +17.6% | 0.00% | +33.3% |
Q1 2023 | $57,960 | +81.9% | 2,520 | -13.7% | 0.00% | +200.0% |
Q4 2022 | $31,868 | +29.4% | 2,921 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $24,624 | +6.6% | 2,921 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $23,105 | -66.6% | 2,921 | 0.0% | 0.00% | -50.0% |
Q1 2022 | $69,169 | -82.8% | 2,921 | -75.1% | 0.00% | -60.0% |
Q4 2021 | $401,747 | +93.0% | 11,747 | 0.0% | 0.01% | +66.7% |
Q3 2021 | $208,157 | -59.9% | 11,747 | +1.7% | 0.00% | -57.1% |
Q2 2021 | $518,454 | +115.6% | 11,552 | +24.4% | 0.01% | +75.0% |
Q1 2021 | $240,456 | +28.5% | 9,284 | 0.0% | 0.00% | +33.3% |
Q4 2020 | $187,165 | +3.1% | 9,284 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $181,502 | +37.9% | 9,284 | +24.5% | 0.00% | +50.0% |
Q2 2020 | $131,655 | +65.7% | 7,455 | +12.7% | 0.00% | +100.0% |
Q3 2019 | $79,470 | – | 6,617 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |